Table 1
Baseline clinical characteristics.
| BASELINE CLINICAL CHARACTERISTICS | ALL (n =616) | MACCE GROUP (n =39) | MACCE-FREE GROUP (n =577) | p-VALUE |
|---|---|---|---|---|
| Age (year) – mean ± SD | 72.81 ± 9.71 | 70.62 ± 9.48 | 72.96 ± 9.72 | 0.145 |
| Sex (Female) – n (%) | 292 (47.4%) | 23 (59.0%) | 269 (46.6%) | 0.135 |
| BMI (kg/m2) – mean ± SD | 24.5 ± 4.2 | 25.1 ± 4.0 | 24.4 ± 4.2 | 0.360 |
| Hypertension – n (%) | 576 (93.5%) | 38 (97.6%) | 535 (93.2%) | 0.502 |
| Cerebrovascular disease – n (%) | 30 (4.9%) | 3 (7.7%) | 27 (4.7%) | 0.428 |
| Diabetes require insulin therapy – n (%) | 7 (1.1%) | 0 (0.0%) | 7 (1.2%) | 0.489 |
| Current or ex-smoker – n (%) | 68 (11.0%) | 2 (5.1%) | 66 (11.4%) | 0.297 |
| Dyslipidemia – n (%) | 467 (75.8%) | 29 (74.4%) | 438 (75.9%) | 0.827 |
| CKD required hemodialysis – n (%) | 74 (12.0%) | 10 (25.6%) | 64 (11.1%) | 0.018 |
| History of previous ACS – n (%) | 118 (19.2%) | 6 (15.4%) | 112 (19.4%) | 0.536 |
| History of previous CABG – n (%) | 49 (8.0%) | 7 (17.9%) | 42 (7.3%) | 0.028 |
| History of previous PCI – n (%) | 252 (40.9%) | 14 (35.9%) | 238 (41.2%) | 0.511 |
| LVEF – mean ± SD 1 | 55.59 ± 17.41 | 50.88 ± 16.18 | 55.94 ± 17.47 | 0.161 |
| Hemoglobin level (g/dL) – mean ± SD 2 | 11.72 ± 1.82 | 10.35 ± 2.25 | 11.82 ± 1.75 | <0.001 |
| Creatinine level (mg/dL) – mean ± SD 3 | 1.90 ± 2.05 | 2.76 ± 2.75 | 1.84 ± 1.97 | 0.048 |
| Indication stable CAD – n (%) | 412 (66.9%) | 23 (59.0%) | 389 (67.4%) | 0.278 |
| Indication NSTE-ACS – n (%) | 187 (30.4%) | 14 (35.9%) | 173 (30.0%) | 0.437 |
| Indication STEMI – n (%) | 16 (2.6%) | 2 (5.1%) | 14 (2.4%) | 0.269 |
| Total lesion per patient – mean ± SD | 1.08 ± 0.27 | 1.07 ± 0.26 | 1.08 ± 0.27 | 0.763 |
[i] ** Bold indicated statistically significant.
1. 40% of LVEF data were missing 2. 18.3% of serum Hb were imputed. 3. 14.3% of serum Cr were imputed.
ACS – acute coronary syndrome; BMI – body mass index; CABG – coronary artery bypass graft; CKD – chronic kidney disease; LVEF – left ventricular ejection fraction; MACCE – major adverse cardiovascular and cerebrovascular events; NSTE-ACS- non-ST elevation acute coronary syndrome; PCI – percutaneous coronary intervention; SD – standard deviation; STEMI – ST-segment elevation myocardial infarction.

Figure 1
Impact of the clinical presentation and the use of intravascular imaging on the occurrence of MACCE. (A) The clinical presentation of the patients. ACS was the combination of non-ST elevation ACS and ST-segment elevation myocardial infarction. (B) Intravascular imaging consisted of intravascular ultrasound or optical coherence tomography.
ACS – acute coronary syndrome; CAD – coronary artery disease; MACCE – major adverse cardiovascular and cerebrovascular events.
Table 2
Angiographic and procedural characteristics.
| CHARACTERISTICS | ALL (n = 663) | MACCE GROUP (n = 43) | MACCE-FREE GROUP (n = 620) | p-VALUE |
|---|---|---|---|---|
| Angiographic characteristics | ||||
| Thrombus (n) – n (%) | 2 (0.3%) | 0 (0.0%) | 2 (0.3%) | 0.713 |
| Ostial lesion (n) – n (%) | 113 (18.3%) | 10 (25.6%) | 103 (17.9%) | 0.224 |
| Chronic total occlusion (n) – n (%) | 46 (7.5%) | 2 (5.1%) | 44 (7.6%) | 0.759 |
| Bifurcation (n) – n (%) | 194 (31.5%) | 11 (28.2%) | 183 (31.7%) | 0.648 |
| Visible severe calcified coronary artery – n (%) | 579 (94.0%) | 37 (94.9%) | 542 (93.9%) | 0.811 |
| Procedural characteristics | ||||
| Femoral access (n) – n (%) | 445 (72.2%) | 30 (76.9%) | 415 (71.9%) | 0.582 |
| 0.330 | |||
| 64 (9.7%) | 3 (7.0%) | 61 (9.8%) | |
| 372 (56.1%) | 19 (44.2%) | 353 (56.9%) | |
| 59 (8.9%) | 6 (14.0%) | 53 (8.5%) | |
| 167 (25.2%) | 15 (34.9%) | 152 (24.5%) | |
| 1 (0.2%) | 0 (0.0%) | 1 (0.2%) | |
| Target lesion B2 or C – n (%) | 652 (98.3%) | 43 (100%) | 609 (98.2%) | 0.378 |
| Balloon dilate before RA – n (%) | 126 (19.0%) | 8 (18.6%) | 118 (19.0%) | 0.945 |
| Post dilate after RA – n (%) | 569 (85.8%) | 38 (88.4%) | 531 (85.6%) | 0.620 |
| Maximum diameter of postdilatation balloon (mm.) – mean ± SD | 3.16 ± 0.56 | 3.18 ± 0.50 | 3.16 ± 0.56 | 0.803 |
| Maximum pressure of postdilatation balloon (ATM.) – mean ± SD | 20.22 ± 5.10 | 21.26 ± 6.00 | 20.14 ± 5.68 | 0.243 |
| Maximum Burr size (mm.) – mean ± SD | 1.55 ± 0.19 | 1.52 ± 0.19 | 1.55 ± 0.18 | 0.372 |
| Use of laser – n (%) | 2 (0.3%) | 1 (2.3%) | 1 (0.2%) | 0.126 |
| Successful RA – n (%) | 659 (99.4%) | 43 (100%) | 616 (99.4%) | 0.597 |
| Number of burr(s) (n) | 0.959 | |||
| 542 (81.8%) | 36 (83.7%) | 506 (81.7%) | |
| 119 (17.9%) | 7 (16.3%) | 112 (18.1%) | |
| Maximum rotational speed x 10000 RPM – mean ± SD | 184.88 ± 18.28 | 189.30 ± 11.36 | 184.57 ± 18.63 | 0.101 |
| Intravenous pacemaker backup – n (%) | 50 (7.5%) | 5 (11.6%) | 45 (7.3%) | 0.362 |
| Intra-aortic balloon pump – n (%) | 26 (3.9%) | 5 (11.6%) | 21 (3.4%) | 0.021 |
| Stent deployment – n (%) | 632 (95.3%) | 41 (95.3%) | 591 (95.3%) | 0.994 |
| POBA only – n (%) | 23 (3.5%) | 0 (0.0%) | 23 (3.7%) | 0.390 |
| Drug-eluting stent – n (%) | 606 (91.4%) | 41 (95.3%) | 565 (91.2%) | 0.582 |
| Diameter of the largest stent (mm.) – mean ± SD | 3.18 ± 0.50 | 3.25 ± 0.52 | 3.17 ± 0.50 | 0.342 |
| Number of stent(s) – n (%) | 0.424 | |||
| 30 (4.5%) | 2 (4.7%) | 28 (4.5%) | |
| 269 (40.6%) | 16 (37.2%) | 253 (40.8%) | |
| 249 (37.6%) | 13 (30.2%) | 236 (38.1%) | |
| 90 (13.6%) | 9 (20.9%) | 81 (13.1%) | |
| 25 (3.8%) | 3 (7.0%) | 212 (3.5%) | |
| Maximum stent length (mm.) – mean ± SD | 26.68 ± 7.71 | 25.54 ± 6.62 | 26.73 ± 7.77 | 0.327 |
| Total stent length in target vessel – mean ± SD | 41.51 ± 19.18 | 43.24 ± 21.24 | 41.39 ± 19.05 | 0.550 |
| Maximum burr size – n (%) | 0.882 | |||
| 110 (17.9%) | 23 (20.0%) | 87 (17.4%) | |
| 297 (48.4%) | 56 (48.7%) | 241 (48.3%) | |
| 196 (31.9%) | 35 (30.4%) | 161 (32.3%) | |
| 10 (1.6%) | 1 (0.9%) | 9 (1.8%) | |
| 1 (0.2%) | 0 (0.0%) | 1 (0.2%) | |
| Intravascular imaging – n (%) | 455 (73.9%) | 20 (51.3%) | 435 (75.4%) | 0.001 |
| Procedural success – n (%) | 481 (78.1%) | 20 (51.3%) | 461 (79.9%) | <0.001 |
| Angiographic success – n (%) | 584 (94.8%) | 33 (92.3%) | 548 (95.0%) | 0.447 |
| Total procedural time (min) – mean ± SD | 91.43 ± 45.49 | 110.36 ± 55.10 | 90.15 ± 44.53 | 0.007 |
| Total fluoroscopic time (min) – mean ± SD | 35.16 ± 17.63 | 40.86 ± 16.31 | 34.78 ± 17.67 | 0.037 |
| Total contrast volume (ml) – mean ± SD | 177.24 ± 74.65 | 175.36 ± 77.68 | 177.37 ± 74.50 | 0.871 |
[i] ** Bold indicated statistically significant.
ATM – atmospheric pressure; LAD – left anterior descending coronary artery; LCX – left circumflex coronary artery; LM – left main coronary artery; POBA – plain balloon angioplasty; RA – rotational atherectomy; RCA – right coronary artery; RPM – revolutions per minute.

Figure 2
Intraprocedural and periprocedural complications. (A) intraprocedural complications that occurred during RA. (B) periprocedural complications post-RA.
MI – myocardial infarction; RA – rotational atherectomy.

Figure 3
Major adverse cardiovascular and cerebrovascular events (MACCE) during follow-up. (A) MACCE during 30-days follow-up. (B) MACCE during one-year follow-up.
Table 3
Primary adverse outcomes during the follow-up period.
| ADVERSE OUTCOMES | TOTAL, n (%) |
|---|---|
| 30-day MACCE – n (%) | 9 (1.5%) |
| 6 (1.0%) |
| 0 (0.0%) |
| (0.5%) |
| 2 (0.3%) |
| 3 (0.5%) |
| 1-year MACCE – n (%) | 39 (6.3%) |
| 10 (1.6%) |
| 0 (0.0%) |
| 17 (2.8%) |
| 22 (3.6%) |
| 29 (4.7%) |
[i] MACCE – major adverse cardiovascular and cerebrovascular events; TLR – target lesion revascularization; TVR – target vessel revascularization.

Figure 4
Multivariate analysis adjusted for the independent risk of developing MACCE.
CABG – coronary artery bypass graft; 95% CI – 95% confidence interval; HR – hazard ratio. * 14.3% of serum Cr values were imputed.
Table 4
Comparison of recently published rotational atherectomy registries that were conducted in Asia.
| CLINICAL TRIAL | POPULATION | NUMBER OF LESIONS | ACS (%) | CENTER(S) | COUNTRY | ANGIOGRAPHIC SUCCESS (%) | FOLLOW UP DURATION | CARDIAC DEATH (%) | STENT THROMBOSIS (%) | TLR (%) | TVR (%) | STROKE (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lee K et al. [22] | 540 | 583 | 60.5% | Multi-center | Korea | 96.4 | 1.5 years | 6.9 | 1.2 | 8.2 | 9.8 | 2.0 |
| Gao W et al. [23] | 540 | 540 | 14.6% | Single-center | China | 96.8 | In-hospital | 1.1 | 0 | – | – | 0 |
| Okai I et al. [24] | 1090 | – | 15% | Multi-center | Japan | 96.2 | 3.8 years | 10.9 | 1.4 | 17.7 | 23 | 5.1 |
| Ray S et al. [25] | 144 | – | 31.25% | Single-center | India | 96.5 | 1 year | 0.7 | – | – | 2.1 | – |
| Our registry | 616 | 663 | 33.1% | Single-center | Thailand | 94.8 | 1 year | 1.6 | 2.8 | 3.6 | 4.7 | 0 |
[i] ACS – acute coronary syndrome; TLR – target lesion revascularization; TVR – target vessel revascularization.
